This site does not support your browser.

We recommend you to upgrade to the latest version:

Resume browsing

Investors Dashboard
Contact
YouTubeLinkedinInstagramFacebookTwitter
  • English
  • Spanish
PharmaMar
PharmaMar
S.A.
  • About PharmaMar
    • About PharmaMar
    • Senior Management
    • Management Team – Oncology Unit
    • Board of Directors
    • Other Businesses
    • PharmaMar in the World
    • Awards & Recognition
    • Corporate Responsibility
    • Our History
  • Patients
    • Therapeutic Indications
    • Collaboration with Patient Associations
    • Clinical trial
  • YONDELIS®
  • Science & Innovation
    • R&D and Innovation
    • Oncology pipeline
    • Cofinanced projects
    • Collaboration with Scientific Associations
    • Publications
    • Mechanisms of Action
  • Shareholders and Investors
    • Financial Information
      • Annual Reports
      • Quarterly Reports
      • Financial Statements (Zeltia)
      • Average Period of Payment to Suppliers
    • Official Notices to the CNMV
      • PharmaMar
      • Zeltia
    • Share Information
      • Share Performance
      • Shares outstanding
      • Dividends
      • Significant Shareholding & Company Owned-Stock
      • Analysts
    • Debt obligations
    • Presentations
    • General Shareholders Meetings
    • Corporate Governance
      • Corporate Bylaws
      • General Shareholders’ Meeting Regulations
      • Shareholder Agreements
      • Board of Directors
      • Board of Directors Regulation
      • Annual Report on Corporate Governance
      • Annual Director Remuneration Report
      • Board Committees
      • Internal Regulation Governing Conduct
    • Contact
    • Merger PharmaMar-Zeltia
    • Política de comunicación con accionistas
  • Newsroom
    • Press Releases
    • Events Calendar
    • Multimedia
      • Videos
      • Infographics
    • Corporate Brochure
  • Careers
MENU CLOSE back  

NdP_PharmaMar_AACR 2017_ok

You are here:
  1. Home
  2. NdP_PharmaMar_AACR 2017_ok

NdP_PharmaMar_AACR 2017_ok

Share

NdP_PharmaMar_AACR 2017_ok

You can also read about
  • (2)Blog
  • (1)Corporate
  • (1)Employment
  • (1)Enviroment
  • Paula Fernández Alarcón
    Media Relations Manager
    pfalarcon@pharmamar.com
  • Miguel Martínez-Cava
    Community Manager
    mmartinez-cava@pharmamar.com

Newsroom

If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.